Hormone Replacement Trial Against ALzheimers' Disease
Recruiting · NCT04312399 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Ghent
View the official record on ClinicalTrials.gov →Interventions studied
blood take
What this trial is about
The influence of postmenopausal hormone treatment on dementia is not clear. Dysfunctions in the metabolism of amyloid in the disease of Alzheimer result in an elevated presence of degradation products in cerebrospinal fluid. The degradation products in blood will be analysed during the trial, to get better insight in menopause and the start of hormonal therapy. Postmenopausal women with and without history of breast cancer will be recruited for the trial.
Who can take part
Age range
40 Years to 65 Years
Sex
Female
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- postmenopausal women
- 40 - 65 years
Exclusion criteria
- Longer than 10 years in menopause
- thyroid dysfunction
- hypertension
- medical history of psychiatric comorbidity
- Alcohol and/or drug abuse
- medical history of neurologic symptoms with cognitive symptoms
Where it is running
1 location listed.
- Ghent university hospital - Ghent, Belgium